Answers are grounded in this paper and cite their sources.
BACKGROUND: OMVax has developed a meningococcal native outer membrane vesicle (NOMV) vaccine containing overexpressed, mutant Factor H binding proteins (FHbps) from subfamilies A and B with reduced FH binding and attenuated endotoxin (NOMV-FHbp). In previous studies, NOMV presented surface antigens in a native environment that elicited high titers of serum bactericidal activity (SBA) in mice and infant macaques. However, the relatively low amounts of NOMV produced by MenB strains has limited vaccine development. METHODS: We describe here a culture medium enabling commercial scale production of NOMV. We investigated the ability of antibodies elicited in mice by NOMV-FHbp alone or in combination with a MenACWY capsular polysaccharide conjugate vaccine to elicit human complement-mediated serum bactericidal activity (SBA) against strains from each capsular group. RESULTS: In CD1 wild-type (WT) mice, anti-NOMV-FHbp antibodies showed significantly greater SBA than those elicited by marketed MenB vaccine MenB-FHbp against five out of six representative MenB strains currently causing disease. The combination NOMV-FHbp+MenACWY vaccine maintained high SBA activity against strains from the different serogroups compared to each individual vaccine. In CEACAM1/FH human transgenic mice, anti-NOMV-FHbp antibodies showed greater or comparable SBA than those elicited by MenB-4C licensed vaccine against two MenB strains expressing FHbp ID 1, an amino acid sequence identical to FHbp ID 1 in the MenB-4C vaccine. CONCLUSIONS: The results show that NOMV-FHbp alone or in combination with MenACWY vaccines has the potential to broaden protection against MenB strains that are not optimally covered by existing vaccines.
No takes yet. Share an insight, caveat, or question.
Giuntini et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: